An inter­na­tional team of researchers recently found that people with MGUS who consumed fruit at least three times a week had a lower risk of pro­gress­ing to multiple myeloma than people with MGUS who consumed fruit less frequently.

The impact of higher fruit consumption on risk of pro­gres­sion was sizable. The statistical models developed by the researchers indicate that eating fruit three times or more each week cut the risk of pro­gres­sion by at least a half.

The researchers also found that the risk of devel­op­ing MGUS was about 35 per­cent lower …

Researchers from the Mayo Clinic con­firmed in a recent study that close relatives of people with multiple myeloma have a higher risk of devel­op­ing MGUS (mono­clonal gam­mop­athy of un­determined sig­nif­i­cance) than members of the general pop­u­la­tion.

In particular, the researchers found that "first-degree relatives" – parents, siblings, and children – of people with multiple myeloma were 2.4 times more likely to have MGUS than the general pop­u­la­tion.

This finding is in line with results of a pre­vi­ous Mayo Clinic study, which was smaller but in­cluded some of the same patients and relatives …

Light chain mono­clonal gam­mop­athy of undetermined sig­nif­i­cance (MGUS) has a very low probability of progressing to symp­tomatic multiple myeloma, accord­ing to the results of a new study by researchers in Germany.

The German researchers found that, with a median follow-up time of 11.5 years, none of the 75 people in their study who had light chain MGUS saw their MGUS progress to symp­tomatic multiple myeloma, amyloidosis, or a related disease.

In fact, in more than half of the 31 cases where the nec­es­sary laboratory results were avail­able, study par­tic­i­pants who initially met …

Hello, myeloma world. How has your Friday been so far?

We have an eclectic mix of five new myeloma-related research studies that we'd like to discuss with you today.

Three of the studies involve laboratory (preclinical) research, which is the sort of research we often leave to discuss later in these reports. But all three of the laboratory studies we cover today address interesting topics, so we will be looking at them first.

The first laboratory study concerns Darzalex (daratumumab) and the possibility of combining it with an investigational anticancer …

Hello, myeloma world. We hope your week has started well.

We have one main item on the agenda for today's edition of Myeloma Morning.

In particular, we want to discuss a topic that is the focus of the only article in our daily list of new myeloma-related research publications, included at the end of this report.

The topic of that article is monoclonal gammopathy of renal significance (MGRS).

Now, most Beacon readers probably have heard of monoclonal gam­mop­athy of undetermined significance (MGUS), an early stage of multiple myeloma that …

Hello again, myeloma world.

As we continue catching up after the recent onslaught of new myeloma-related research, we're pleased to report that it's a sunny spring day outside. More importantly, our top story today reflects Mother Nature's pleasant disposition.

In particular, there is updated data about multiple myeloma survival in the United States, and it's good news.

It's just an annual update – a single new value for survival five-years from the time of diagnosis. And it's for patients diagnosed all the way back in 2008 – the most recent year for …

The annual meetings of the American Society of Clinical Oncology (ASCO) and the Euro­pean He­ma­tol­ogy Asso­ci­a­tion (EHA) took place earlier this month. The two meetings were attended by tens of thousands of physi­cians from around the world, and featured a myriad of oral pre­sen­ta­tions, posters, and e-abstracts summarizing the re­­sults of new on­col­ogy- and he­ma­tol­ogy-related re­search.

Included in the re­search pre­sented at the two meetings were more than 200 stud­ies discussing new mul­ti­ple myeloma-related findings.

In addi­tion to the two large meetings held earlier this month, the Inter­na­tion­al Myeloma Work­ing Group (IMWG) …